contact[at]op2lysis.com

pilelabs
  • The company
  • The Technology
  • Products
  • Indications
  • News
  • Contact
  • Français

Daily Archives: 15 September 2022

  1. Home
  2. 2022
  3. September
  4. 15
  • Op2Lysis
  • September 2022
  • Corporate
Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission
Read More

Articles récents

  • Funding for the ThromboSTROKE collaborative research project
  • Sucessful DRF toxicology Study
  • Retrospective – 2023 in a nutshell
  • Nominated for the GALIEN USA 2023 award “Best Startup”
  • Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience  in cerebral haemorrhage

Archives

  • October 2024
  • September 2024
  • January 2024
  • October 2023
  • September 2023
  • July 2023
  • January 2023
  • December 2022
  • September 2022
  • April 2022
  • January 2022

Catégories

  • Corporate
  • Event
  • Press Release
  • Technology
gym-footer-logo

Biotechnology company that researches and develops innovative medicines

Supported by
europe
bpi
wallonie

SItemap

  • Contact
  • home
  • Indications
  • Legal Notice
  • News
  • Products
  • The company
  • The Technology

Recent Posts

Nominated for the GALIEN USA 2023 award “Best Startup”
October 12, 2023
Funding for the ThromboSTROKE collaborative research project
October 15, 2024
Sucessful DRF toxicology Study
September 03, 2024

Contact

  • FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication